Search
Search Results
-
Preventive treatment with alendronate of loss of bone mineral density in acute traumatic spinal cord injury. Randomized controlled clinical trial
Study designRandomized controlled clinical trial of two parallel groups.
ObjectivesAnalyse the efficacy of primary prevention with alendronate on...
-
Alendronate inhibits triglyceride accumulation and oxidative stress in adipocytes and the inflammatory response of macrophages which are associated with adipose tissue dysfunction
Alendronate, a bisphosphonate used to prevent osteoporosis, stimulates osteogenesis but impairs adipogenesis. Different clinical trials suggest that...
-
Alendronate Augments Lipid A–Induced IL-1α Release via Activation of ASC but Not Caspase-11
Nitrogen-containing bisphosphonates (NBPs), such as alendronate (ALN), are anti-bone-resorptive drugs that have inflammatory side effects. We...
-
Bone-Targeted Dual Functional Lipid-coated Drug Delivery System for Osteosarcoma Therapy
Purpose or ObjectiveOsteosarcoma is well-known for its high incidence in children and adolescents and long-term bone pain, which seriously reduces...
-
A remarkable in vitro cytotoxic, cell cycle arresting and proapoptotic characteristics of low-dose mixed micellar simvastatin combined with alendronate sodium
The objective of the present study was to screen the effect of increased simvastatin (SVS) solubility, through mixed micelles as a model approach, on...
-
Open-label clinical trial of alendronate after teriparatide therapy in people with spinal cord injury and low bone mineral density
Study designNon-randomized open-label clinical trial of oral alendronate after teriparatide therapy in people with spinal cord injury (SCI) and low...
-
An Evidence-Based Practice Approach to Evaluating Biotechnologically Derived Medications
Over the last 1–2 decades, a number of different therapeutic proteins have been developed using pharmaceutical biotechnology. This chapter uses six...
-
Histamine acts via H4-receptor stimulation to cause augmented inflammation when lipopolysaccharide is co-administered with a nitrogen-containing bisphosphonate
Objective and methodsNitrogen-containing bisphosphonates (NBPs, anti-bone-resorptive agents) have inflammatory side-effects. Alendronate (Ale, an...
-
Does the use of bisphosphonates during pregnancy affect fetal outcomes? A systematic review
PurposeThis systematic review aimed to determine the effects of maternal exposure to bisphosphonates (BPs) during pregnancy on neonatal outcomes. It...
-
Romosozumab in osteoporosis: yesterday, today and tomorrow
Osteoporosis is a systemic bone disease characterized by low bone mass, microarchitectural deterioration, increased bone fragility, and fracture...
-
Association between SOST gene polymorphisms and response to alendronate treatment in postmenopausal Chinese women with low bone mineral density
The aim of this study was to explore the allelic association between SOST polymorphisms and the variance of clinical effects of alendronate in...
-
Role of Block Co-Polymers in Drug Delivery
Block co-polymers are extensively used in drug delivery applications, including the preparation of advanced co-polymeric nanocarrier systems and...
-
Core decompression combined with local DFO administration loaded on polylactic glycolic acid scaffolds for the treatment of osteonecrosis of the femoral head: a pilot study
BackgroundDeferoxamine (DFO) angiogenesis induction potential has been demonstrated in earlier studies, but not in the osteonecrosis of the femoral...
-
Reduced Bone Modeling and Unbalanced Bone Remodeling: Targets for Antiresorptive and Anabolic Therapy
Bone loss during advancing age is the net result of reduced modeling-based bone formation upon the outer (periosteal) envelope and unbalanced...
-
Osteoporosis
Osteoporosis is a systemic skeletal disease associated with an increased risk of fracture and characterized by reduced bone mass and qualitative...
-
Medication-induced osteonecrosis of the jaw: a review of cases from the Food and Drug Administration Adverse Event Reporting System (FAERS)
BackgroundOsteonecrosis of the jaw (ONJ) is a rare but serious adverse drug reaction (ADR) commonly associated with bisphosphonate and denosumab...
-
Impacts of bisphosphonates on the bone and its surrounding tissues: mechanistic insights into medication-related osteonecrosis of the jaw
Bisphosphonates are widely used as anti-resorptive agents for the treatment of various bone and joint diseases, including advanced osteoporosis,...
-
Current knowledge of bone-derived factor osteocalcin: its role in the management and treatment of diabetes mellitus, osteoporosis, osteopetrosis and inflammatory joint diseases
Osteocalcin (OC) is the most abundant non-collagenous and osteoblast-secreted protein in bone. It consists of two forms such as carboxylated OC (cOC)...
-
Influence of non-osteoporotic treatments in patients on active anti-osteoporotic therapy: evidence from the OSTEOMED registry
PurposeTo evaluate the effect of different non-osteoporotic drugs on the increase or decrease in the risk of incident fragility fractures (vertebral,...
-
Medication-related osteonecrosis of the jaw (MRONJ): a review of pathogenesis hypothesis and therapy strategies
Medication-related osteonecrosis of the jaw (MRONJ), a severe side effect caused by antiresorptive antiangiogenic medication, particularly...
